Anna Schuh, MD, PhD

Professor
Churchill Hospital, Oxford University, United Kingdom

N/A

Poster(s):

• 1102 - Unravelling Prognostic Significance: Long-Read Nanopore Sequencing of TP53 and IGHV in Chronic Lymphocytic Leukaemia Patients in Tanzania.

• 1121 - High-risk molecular features eclipse genomic complexity in predicting CLL patient outcomes; Insights from the UK CLL4, ARCTIC and ADMIRE trials.

• 1433 - Ibrutinib plus venetoclax with measurable residual disease-guided duration of treatment is superior to both ibrutinib monotherapy and fludarabine-cyclophosphamide-rituximab for previously untreated chronic lymphocytic leukaemia: Report of the Phase III UK NCRI FLAIR study.

• 1803 - Real-world Treatment Outcomes among Patients with High-Risk CLL/SLL Receiving Venetoclax-Based Therapy in 1L or 2L: An Updated International Study

• 2003 - Evaluating Gaps and Opportunities in Chronic Lymphocytic Leukemia Treatment Access: Institutional Capacity Assessments in 18 LMICs